Opportunity Information: Apply for CDC RFA PS09 981
Apply for CDC RFA PS09 981
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "HIV/AIDS surveillance and service data analysis in the Republic of Haiti under the President s Emergency Plan for AIDS Relief (PEPFAR)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.067 Global AIDS.
- This funding opportunity was created on Mar 31, 2009 and posted on Mar 31, 2009.
- Applicants must submit their applications by May 29, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $300,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Eligible applicants Eligible applicants that can apply for this funding opportunity appear below Public, non profit organizations Private, non profit organizations For profit organizations Small, minority, and women owned businesses Universities Colleges Research institutions Hospitals Community based organizations Faith based organizations Federally recognized Indian tribal Governments Indian tribes Indian tribal organizations U.S. State and local Governments or their Bona Fide Agents (this includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of the Marshall Islands, and the Republic of Palau) Political subdivisions of U.S. States (in consultation with States) A Bona Fide Agent is an agency/organization identified by a state as eligible to submit an application under the States eligibility in lieu of a State application. If applying as a bona fide agent of a State or local Government, a letter from the State or local Government as documentation of the status is required. Place this documentation behind the first page of the application form.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This CDC cooperative agreement opportunity (Funding Opportunity Number CDC RFA PS09-981) supports HIV/AIDS surveillance and service data analysis in the Republic of Haiti under the President's Emergency Plan for AIDS Relief (PEPFAR). It is a discretionary health funding announcement intended to strengthen Haiti's ability to measure the direction of the HIV epidemic, detect related sexually transmitted infection trends, and use routine and special study data to improve program performance and inform policy. The overall focus is on generating reliable, repeatable evidence about HIV and syphilis burden in key populations, monitoring emerging threats like HIV drug resistance, and assessing how well antiretroviral therapy (ART) services are being delivered across selected PEPFAR-supported sites.
A central activity is the implementation of periodic Antenatal Clinic (ANC) sero-surveys. These surveys are designed to track trends in HIV and syphilis among pregnant women who attend ANC services, a population often used for sentinel surveillance because it can provide a consistent window into ongoing transmission patterns. By repeating these surveys over time, the program can observe whether prevalence is rising, stable, or declining, and can also compare patterns across geographic areas and facilities. Including syphilis alongside HIV reflects an integrated approach to monitoring sexually transmitted infections and maternal health risks, which can guide prevention priorities and the targeting of screening and treatment services.
Another major component is an HIV drug resistance threshold study. The intent is to evaluate the extent of transmitted HIV drug resistance at sero-sentinel surveillance sites, which helps programs understand whether newly infected individuals are acquiring virus strains that already carry resistance to commonly used antiretroviral medications. This type of assessment can flag early warning signs that current first-line regimens may become less effective over time, and it can support decisions about treatment guidelines, regimen selection, and the need for enhanced adherence and viral load monitoring strategies. In practical terms, the study is meant to provide actionable information on whether drug resistance is an emerging obstacle to treatment success in the broader population.
The opportunity also emphasizes periodic triangulation of data, meaning the systematic comparison and combined interpretation of multiple data sources. The goal is to demonstrate program impact, identify gaps and areas for improvement, guide where new interventions should be introduced, and strengthen or refine existing programming. Triangulation typically draws from surveillance findings, routine service delivery data, laboratory information, and other monitoring and evaluation inputs to produce a clearer picture than any single dataset can provide. In this announcement, triangulation is explicitly tied to decision-making: using evidence to reallocate resources, adjust implementation approaches, and support potential policy changes based on what the combined data indicate.
In addition, the project calls for cohort studies at a selected number of ART sites within the PEPFAR network. These studies are intended to capture key aspects of patient care and treatment outcomes at baseline, at six months, and then annually. The aim is to assess ART site performance in delivering treatment, which commonly includes evaluating retention in care, treatment initiation processes, follow-up practices, and indicators of clinical and program quality over time. By using repeated follow-ups, cohort studies can show whether patients are staying in care and benefiting from services, and they can highlight where facilities may need targeted support to improve continuity and effectiveness of treatment delivery.
Administratively, this is a cooperative agreement, meaning CDC would typically expect substantial involvement and collaboration during implementation, as opposed to a more hands-off grant mechanism. The announcement anticipated a single award, with an estimated total funding amount of $300,000 and a ceiling and floor both set at $300,000, indicating a fixed award size for the one selected recipient. There is no cost-sharing or matching requirement. The opportunity was posted March 31, 2009, with an application closing date of May 29, 2009, and it was later archived on June 28, 2009.
Eligibility is broad and includes public and private nonprofit organizations, for-profit organizations, small/minority/women-owned businesses, universities and colleges, research institutions, hospitals, community-based and faith-based organizations, federally recognized tribal governments and organizations, and U.S. state and local governments or their bona fide agents (including certain U.S. territories and affiliated jurisdictions). Applicants seeking to apply as a bona fide agent of a state or local government were required to include documentation (a letter) confirming that status. The funding is administered by the Centers for Disease Control and Prevention (CDC), and the notice provided a CDC Procurement and Grants Office technical information management contact for assistance accessing the full announcement.
Frequently Asked Questions (FAQ)
What is this funding opportunity?
This is a CDC cooperative agreement funding opportunity (Funding Opportunity Number CDC RFA PS09-981) that supports HIV/AIDS surveillance and service data analysis activities in the Republic of Haiti under the President's Emergency Plan for AIDS Relief (PEPFAR).
What is the main purpose of the award?
The purpose is to strengthen Haiti's capacity to measure the direction of the HIV epidemic, detect related sexually transmitted infection trends (including syphilis), and use both routine data and special study data to improve program performance and inform policy.
What types of evidence and outcomes is the project trying to generate?
The project focuses on generating reliable, repeatable evidence about HIV and syphilis burden in key populations, monitoring emerging threats such as HIV drug resistance, and assessing how well antiretroviral therapy (ART) services are being delivered across selected PEPFAR-supported sites.
What does "cooperative agreement" mean in this announcement?
This is a cooperative agreement, which generally indicates CDC expects substantial involvement and collaboration during implementation, rather than a more hands-off relationship that is typical of some other grant mechanisms.
Where will the supported work take place?
The work supported by this opportunity is focused on the Republic of Haiti, including selected PEPFAR-supported sites for surveillance and ART service assessment activities.
What is the role of PEPFAR in this opportunity?
The opportunity is tied to PEPFAR and supports surveillance and service data analysis activities aligned with PEPFAR-supported HIV program sites and monitoring needs in Haiti.
What are Antenatal Clinic (ANC) sero-surveys in the context of this project?
ANC sero-surveys are periodic surveys conducted among pregnant women attending antenatal clinic services. In this opportunity, they are used as sentinel surveillance to track trends in HIV and syphilis over time and compare patterns across geographic areas and facilities.
Why include pregnant women attending ANC services as a surveillance population?
In this announcement, pregnant women attending ANC services are described as a population often used for sentinel surveillance because it can provide a consistent window into ongoing transmission patterns and allow repeat measurement over time.
Why does the opportunity include syphilis alongside HIV in ANC sero-surveys?
Including syphilis alongside HIV reflects an integrated approach to monitoring sexually transmitted infections and maternal health risks, which can help guide prevention priorities and the targeting of screening and treatment services.
What is meant by an HIV drug resistance threshold study?
The HIV drug resistance threshold study is intended to evaluate the extent of transmitted HIV drug resistance at sero-sentinel surveillance sites. The goal is to understand whether newly infected individuals are acquiring HIV strains that already have resistance to commonly used antiretroviral medications.
How would the drug resistance study be used programmatically?
The announcement describes the study as providing actionable information and early warning signs about whether current first-line regimens may become less effective over time, supporting decisions about treatment guidelines, regimen selection, and the possible need for enhanced adherence and viral load monitoring strategies.
What does "triangulation of data" mean in this funding opportunity?
Triangulation refers to the systematic comparison and combined interpretation of multiple data sources. In this announcement, it is used to demonstrate program impact, identify gaps and areas for improvement, guide where new interventions should be introduced, and strengthen or refine existing programming.
What kinds of data sources are considered for triangulation under this announcement?
The announcement describes triangulation as typically drawing from surveillance findings, routine service delivery data, laboratory information, and other monitoring and evaluation inputs to provide a clearer picture than any single dataset alone.
How is triangulation tied to decision-making in this opportunity?
Triangulation is explicitly linked to decision-making, including using evidence to reallocate resources, adjust implementation approaches, and support potential policy changes based on what the combined data indicate.
What are the cohort studies at ART sites expected to do?
The project calls for cohort studies at a selected number of ART sites within the PEPFAR network to capture key aspects of patient care and treatment outcomes at baseline, at six months, and then annually, in order to assess ART site performance in delivering treatment.
What time points are specified for ART cohort follow-up?
The announcement specifies collecting information at baseline, at six months, and then annually for the cohort studies at selected ART sites.
What aspects of ART service performance are being assessed?
The announcement indicates these cohort studies are intended to assess ART site performance and commonly include evaluating retention in care, treatment initiation processes, follow-up practices, and indicators of clinical and program quality over time.
How many awards were anticipated?
The announcement anticipated a single award.
What is the total funding amount for this opportunity?
The estimated total funding amount is $300,000, and both the ceiling and floor are set at $300,000, indicating a fixed award size for the one selected recipient.
Is there any cost-sharing or matching requirement?
No. The announcement states there is no cost-sharing or matching requirement.
When was the opportunity posted, and when did it close?
The opportunity was posted on March 31, 2009, with an application closing date of May 29, 2009.
What is the current status of the announcement?
The announcement was later archived on June 28, 2009.
Who is eligible to apply?
Eligibility is broad and includes public and private nonprofit organizations, for-profit organizations, small/minority/women-owned businesses, universities and colleges, research institutions, hospitals, community-based and faith-based organizations, federally recognized tribal governments and organizations, and U.S. state and local governments or their bona fide agents (including certain U.S. territories and affiliated jurisdictions).
What documentation is required if applying as a bona fide agent of a state or local government?
Applicants applying as a bona fide agent of a state or local government were required to include documentation (a letter) confirming that status.
Which federal agency administers this opportunity?
The funding is administered by the Centers for Disease Control and Prevention (CDC).
Where can applicants get technical help accessing the full announcement?
The notice provided a CDC Procurement and Grants Office technical information management contact for assistance accessing the full announcement.
Browse more opportunities from the same agency: Centers for Disease Control and Prevention
Browse more opportunities from the same category: Health
Next opportunity: Supporting the National Blood Transfusion Service (NBTS) in the Implementation and Expansion of Blood Safety Activities in the Republic of Kenya under the President s Emergency plan for AIDS Relief (PEPFAR)
Previous opportunity: Native Hawaiian Health Care
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA PS09 981
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA PS09 981) also looked into and applied for these:
| Funding Opportunity |
|---|
| Supporting the National Blood Transfusion Service (NBTS) in the Implementation and Expansion of Blood Safety Activities in the Republic of Kenya under the President s Emergency plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 984 Funding Number: CDC RFA PS09 984 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,500,000 |
| Strengthening HIV Strategic Information Activities in the Republic of Kenya under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 990 Funding Number: CDC RFA PS09 990 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Technical assistance to the National AIDS Control Organization (NACO) of India for HIV/AIDS Care and Support, Surveillance, Laboratory Systems, Human Capacity Development, and Monitoring and Evaluation under the President s Emergency Plan for AIDS Re Apply for CDC RFA PS09 994 Funding Number: CDC RFA PS09 994 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Global Prevention of Non Communicable Disease Prevention and Promotion of Health Apply for CDC RFA DP09 909 Funding Number: CDC RFA DP09 909 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Strengthening Health Systems and Coordination for HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Swaziland under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 911 Funding Number: CDC RFA PS09 911 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Provision of HIV/AIDS and TB related laboratory support and technical assistance services in the Kingdom of Swaziland under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 912 Funding Number: CDC RFA PS09 912 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| Developing Advanced Laboratory Systems in the Socialist Republic of Vietnam under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 9106 Funding Number: CDC RFA PS09 9106 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $325,000 |
| Building and Improving Laboratory Capacity and Quality in the Kingdom of Lesotho under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 923 Funding Number: CDC RFA PS09 923 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,105,000 |
| Support to the Ministry of Health and Social Welfare to Strengthen Health Systems and Coordinate HIV/AIDS Prevention, Care and Treatment Programs in the Kingdom of Lesotho under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 924 Funding Number: CDC RFA PS09 924 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $255,000 |
| Support for a Comprehensive HIV and AIDS Program at the District Level in the Republic of South Africa under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 931 Funding Number: CDC RFA PS09 931 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,000,000 |
| HIV Prevention among Students and Faculty at Pre Service Institutions in the Republic of Mozambique under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 943 Funding Number: CDC RFA PS09 943 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Implementation of a Primary Health Care Program in South Africa under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 951 Funding Number: CDC RFA PS09 951 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,500,000 |
| Implementation of an HIV Care and Support Program in the Republic of South Africa under the President s Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 956 Funding Number: CDC RFA PS09 956 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Strengthening Public Health Laboratory Systems in the Republic of Kenya under the President s Emergency Fund for AIDS Relief (PEPFAR) Apply for CDC RFA PS09 965 Funding Number: CDC RFA PS09 965 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,800,000 |
| Part C EIS CATEGORICAL GRANT PROGRAM TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE Apply for HRSA 10 007 Funding Number: HRSA 10 007 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Novel statistical methods for human gene expression quantitative trait loci (eQTL) analysis (R01) Apply for RFA RM 09 006 Funding Number: RFA RM 09 006 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| FY 2009 CONGRESSIONAL EARMARKS (CEA) Apply for HHS 2009 CMS CEA 0007 Funding Number: HHS 2009 CMS CEA 0007 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $666,000 |
| Grants to Support the Hispanic Health Services Research Grant Program Apply for HHS 2009 CMS HHS 0005 Funding Number: HHS 2009 CMS HHS 0005 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $100,000 |
| Coordinating Center for Organ Transplant Clinical Trials (U01) Apply for RFA AI 09 015 Funding Number: RFA AI 09 015 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Grants to Support the Historically Black Colleges and Universities Apply for HHS 2009 CMS HBCU 0006 Funding Number: HHS 2009 CMS HBCU 0006 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $100,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA PS09 981", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.